



deprescribing.org
Reducing medications safely
to meet life's changes | Moins de médicaments, sécuritairement –
pour mieux répondre aux défis de la vie

Developing and implementing deprescribing guidelines

Barbara Farrell BScPhm, PharmD, FCSHP
European Society of Hospital Pharmacists
March 2017



Disclosure

- Relevant financial relationships
 - None

Acknowledgments



- *Deprescribing guidelines developed with funding from the Government of Ontario*, the Ontario Pharmacy Research Collaboration and Canadian Institutes of Health Research*
- **The views expressed in this presentation are the views of the author(s)/presenter(s) and do not necessarily reflect those of the Province.*



deprescribing.org

Self-assessment questions

1. Deprescribing should be tested by recommending to patients that they periodically choose to stop taking medications (T/F)
2. Evidence-based deprescribing guidelines consider harm of continuing a drug in addition to evidence for the harm/benefit of stopping a drug (T/F)
3. There are not enough tools available to help make decisions about deprescribing (T/F)



deprescribing.org

Objectives

- Participants will be able to
 1. Describe how the concept of deprescribing contributes to management of polypharmacy
 2. List resources and tools available to help with making deprescribing decisions
 3. Assist patients and prescribers with prioritizing medications for deprescribing and carrying out deprescribing safely



What problem are we trying to solve^{1,2}

- Polypharmacy: more medications than needed, or for which harm outweighs benefit
- Increases risk of:
 - Adverse drug reactions, drug interactions, prescribing cascades
 - Falls, fractures
 - Functional and cognitive decline
 - Nonadherence
 - Hospitalizations and higher healthcare costs
- Especially for the elderly who handle and respond to drugs differently, are often frail and not represented in research






Why are the elderly at risk?¹

- Age-related changes
 - Absorption: altered bioavailability (↓ transport, ↓ first pass)
 - Distribution: ↑ body fat, ↓ body water
 - Metabolism: ↓ oxidative metabolism
 - Excretion: ↓ renal function (increases half-life)
- Altered pharmacodynamics
 - Changes in receptor numbers, post-receptor alterations
 - Impaired homeostatic mechanisms
- Increasing comorbidity

How big is the problem?^{3,4}

- 2/3 Canadian seniors are prescribed at least 5 prescription medications
- Who takes 10 or more?
 - 27% over 65 years
 - 40% over 85 years
 - 66% in long-term care homes
- \$419 million spent on PIMs
- \$1.4 billion in incremental health care expenditure due to PIMs




()

Deprescribing

- “The planned and supervised process of dose reduction or stopping of medication that may be causing harm or no longer be of benefit. The goal of deprescribing is to reduce medication burden and harm, while maintaining or improving quality of life.”
- **“Deprescribing is part of good prescribing – backing off when doses are too high, or stopping medications that are no longer needed.”**

Making deprescribing decisions



UNIVERSITY OF BRUYÈRE
Bruyère
RESEARCH INSTITUTE



deprescribing.org

Goals in the elderly

- Maintain and improve
 - Physical functioning (e.g. activities of daily living)
 - Psychological functioning (e.g. cognition, depression)
 - Social functioning (e.g. social activities, support systems)
 - Overall health and well-being (e.g. general health perception)



UNIVERSITY OF BRUYÈRE
Bruyère
RESEARCH INSTITUTE



deprescribing.org

Challenges and enablers⁵



- Prescribers
 - Awareness/insight
 - Inertia
 - Self-efficacy
 - Feasibility
 - Devolving responsibility
 - Patient and prescriber complexity
 - Treatment guidelines
- Patients
 - Vast majority hypothetically willing
 - Belief in appropriateness
 - Fear
 - Influences: GP, family, friends, media, previous experience
 - Medication dislike
 - Knowing there is a process



open
ONTARIO PHARMACY
EVIDENCE NETWORK

Taking action on deprescribing

The Deprescribing Guidelines Research Program

<http://www.open-pharmacy-research.ca/research-projects/emerging-services/deprescribing-guidelines/>




Deprescribing guidelines research

- Aim
 - Develop, implement, evaluate evidence-based deprescribing guidelines to facilitate management of polypharmacy




Methods⁷

Develop and Pilot Guidelines



Developmental Evaluation



Rapid DE Analysis
Methods

Implementation
Research

Rigorous
Qualitative
Analysis Methods



Guideline development to date

	PPI Guideline	BZRA Guideline	AP Guideline	AHG Guideline
Team	Barb Farrell, Paul Moayeddi, Kevin Pottie, Carlos Rojas-Fernandez, Kate Walsh (Shannon Gordon, Joy Rashid, Taline Boghassian, Vivian Welch, Lisa Pizzola)	Kevin Pottie, Simon Davies, Vivian Welch, Jean Grenier, Cheryl Sadowski, Anne Holbrook, Cynthia Boyd, Robert Swenson, Barbara Farrell (Wade Thompson, Andy Ma, Elli Polemiti, Sonia Hussain, Olanrewaju Medu)	Lise Bjerre, Barb Farrell, Carlos Rojas-Fernandez, Andrew Wiens, Genevieve Lemay, Lalitha Raman-Wilms, Lisa McCarthy, Lyla Graham, Samir Sinha, Vivian Welch (Matt Hogel, Cody Black, Jessica Tang, Wade Thompson)	Barb Farrell, Wade Thompson, Lisa McCarthy, Carlos Rojas-Fernandez, Heather Lochnan, Salima Shamji, Ross Upshur, Manon Bouchard, Vivian Welch (Cody Black)
Develop	Nov 2013-May 2014	July 2014-Jan 2015	Feb-May 2015	June 2015-June 2016
Pilot	June-Nov. 2014	Feb-May/June 2015	June-Nov 2015	Not piloted
Publish	In press (CFP)	In press (CFP)	Under review (CFP)	Under review (CFP)

From thought process to guidelines

Typical thought process

1. What factors warrant continued use?
2. Under what conditions is it appropriate to deprescribe (taking appropriate targets and potential for harm into account)? And, what is the evidence for the effectiveness and safety of deprescribing?
3. How can the patient/family be engaged in the process?
4. How should the medication be deprescribed?
5. What should be monitored? And, how often?
6. How should symptoms be managed?
7. When should treatment be restarted?

Developing a guideline⁸

1. Define scope and purpose
2. Generate key clinical questions
3. Set criteria for admissible evidence; conduct systematic review(s)
4. Synthesize evidence (including harms, patient values, resource implications, other guidelines) (GRADE)
5. Formulate recommendations; assess strength (GRADE)
6. Add clinical considerations
7. Conduct clinical and stakeholder review (AGREE II)
8. Update pre-publication



Selected outputs



Findings

- There is an appetite for such guidelines; many priorities identified⁶
- Using an evidence-based approach (with GRADE and AGREE II) was time-consuming and costly but increased trustworthiness
- Deprescribing decision-support algorithms easily implemented into routine pharmacist-physician LTC medication reviews; appeared to increase self-efficacy for deprescribing⁹ + reduce targeted medication use¹⁰
- In LTC, need patient/family/staff buy-in + better communication strategies
- Implementation in Family Health Teams more challenging due to competing priorities, EMR limitations + lack of documented reason



Case examples



PPIs


- High prevalence of use often with no documented indication
- Expense and pill burden
- Potentially harmful

23 April 2017

Bruyère



deprescribing.org



© Use freely, with credit to the authors. Not for commercial use. Do not modify or translate without permission.
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Download: <https://deprescribing.org/ppt/01-0101-deprescribing.org-for-everyone-11-2016.pdf>

Issaoui B, Pothier K, Truchon M, Desjardins Y, Pothier L, Mouchet J, Nadeau-Ribault L, Wain K, Welch V, Moynihan P, Goggin
Evidence-based clinical practice guideline for deprescribing proton pump inhibitors. Deprescribing manuscript



deprescribing.org



Bruyère



PPI Availability

PPI	Standard dose (healing) (once daily)*	Low dose (maintenance) (once daily)
Omeprazole (Zegerid®) - Capsule	30 mg*	10 mg*
Esomeprazole (Nexium®) - Tablet	30 ^a or 40 ^a mg	20 mg
Lansoprazole (Prevacid®) - Capsule	30 mg*	15 mg*
Dexlansoprazole (Dexlan®) - Tablet	30 ^a or 60 ^a mg	30 mg
Pantoprazole (Protonix®, Pantoloc®) - Tablet	40 mg	20 mg
Rabeprazole (Pariet®) - Tablet	30 mg	10 mg

Legend

- a** Non-erosive reflux disease
- b** Reflux esophagitis
- c** Symptomatic non-erosive gastroesophageal reflux disease
- d** Healing of erosive esophagitis
- e** Can be sprinkled on food

* Standard dose PPI taken BID only indicated in treatment of peptic ulcers caused by *H. pylori*. PPI should generally be stopped once eradication therapy is complete unless risk factors warrant continuing PPI (see guideline for details).

Key

GERD = gastroesophageal reflux disease
NSAID = nonsteroidal anti-inflammatory drugs
H2RA = H2 receptor antagonist

SR = systematic review
GRADE = Grading of Recommendations Assessment, Development and Evaluation

Engaging patients and caregivers

Patients and/or caregivers may be more likely to engage if they understand the rationale for deprescribing (risks of continued PPI use; long-term therapy may not be necessary), and the deprescribing process.

PPI side effects

- When an ongoing indication is unclear, the risk of side effects may outweigh the risk of benefit
- PPIs are associated with higher risk of fractures, *C. difficile* infections and diarrhea, community-acquired pneumonia, vitamin B12 deficiency and hypomagnesemia
- Common side effects include headache, nausea, diarrhea and rash

Tapering doses

- No evidence that one tapering approach is better than another
- Lowering the PPI dose (for example, from twice daily to once daily, or halving the dose, or taking every second day) OR stopping the PPI and using it on-demand are equally recommended strong options
- Choose what is most convenient and acceptable to the patient

On-demand definition


Daily intake of a PPI for a period sufficient to achieve resolution of the individual's reflux-related symptoms; following symptom resolution, the medication is discontinued until the individual's symptoms recur, at which point, medication is again taken daily until the symptoms resolve.

© Use freely, with credit to the authors. Not for commercial use. Do not modify or translate without permission.
This work is licensed under a Creative Commons Attribution Non-Commercial-ShareAlike 4.0 International License.
Citation: deprescribing.org, at Risk deprescribing.org for more information.
David B. Brown, R. Thompson, M. Thompson, A. Pritchard, L. Wood, J. Hays, S. Brown, C. Smith, R. Smith, M. Thompson, R. Gray.
Evidence-based clinical advice guidelines for deprescribing proton pump inhibitors. Unpublished manuscript.

Mr. D. – 62 year old male

- Pantoprazole 40mg bid started by primary care provider 4 years ago for heartburn related to stress and diet
- Heartburn relieved since starting PPI (no endoscopy)
- No history ulcer
- Is there an opportunity?
- Why do it?
- How?






Mrs A. – 89 year old female (LTC)

Medication	Reason
Alendronate 70mg once weekly Vitamin D 1000 IU daily	Osteoporosis
Ramipril 10mg daily Bisoprolol 2.5mg daily Atorvastatin 40mg daily ASA 81mg daily	Secondary prevention (CVD)
Levothyroxine 50mcg daily	Hypothyroidism
Tiotropium 18mcg daily Salbutamol prn	COPD
Omeprazole 20mg daily	Unknown



**Is there an opportunity?
Why do it?
How?**



Other PPI deprescribing opportunities

- PPI started for stress ulcer prophylaxis; out of ICU
- PPI started for temporary heartburn during pregnancy or in hospital (3 days without symptoms)
- PUD due to NSAID or *H. pylori* treated x 2-12 weeks; no longer on NSAID
- GERD diagnosis – treated for 8 weeks and no symptoms

PPI Challenges

- How would you approach these issues?
 - “I tried stopping once before and got really bad heartburn that night”
 - “I’m worried my patient will bleed”





Antihyperglycemics – balancing benefit/risk

- Shifting goals of treatment as people age (QoL, reducing treatment burden vs. prolonging life/reducing risk)
- Time to benefit may be longer than life expectancy
- May be at higher risk of hypoglycemia, with complications such as falls, fractures, cognitive impairment, seizures, and hospitalisation
- Risk is greatly increased in the frail elderly
- No evidence demonstrates benefits of traditional glycemic control for older adults who are frail, demented, or have limited life expectancy



Diabetes Canada targets



© Deprescribing with credit to the authors. Not for commercial use. Do not modify or translate without permission. This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License. Contact deprescribing@bruyere.ca or visit deprescribing.org for more information.

Farrell B, Black C, Thompson W, McCarthy L, Pogue-Geile M, Luchman H, Shugart L, Webb V, Beauchamp M, Lippman R. 2016. Evidence-based clinical practice guidelines for deprescribing antihyperglycemics. Unpublished manuscript.





Antihyperglycemics and Hypoglycemia Risk

Drug	Cause hypoglycemia?
Alpha-glucosidase inhibitor	No
Dipeptidyl peptidase-4 (DPP-4) inhibitors	No
Glucagon-like peptide-1 (GLP-1) agonists	No
Insulin	Yes (highest risk with regular insulin and MPA insulin)
Meglitinides	Yes (low risk)
Metformin	No
Sodium-glucose linked transporter 2 (SGLT2) inhibitors	No
Sulfonylureas	Yes (highest risk with glyburide and lower risk with glimepiride)
Thiazolidinediones (TZDs)	No

Drugs affecting glycemic control

- Drugs reported to cause hyperglycemia (when these drugs stopped, can result in hypoglycemia from antihyperglycemic drugs) e.g. quinolones (especially gatifloxacin), beta-blockers (except carvedilol), thiazides, atypical antipsychotics (especially olanzapine and clozapine), corticosteroids, calcineurin inhibitors (such as cyclosporine, sirolimus, tacrolimus), protease inhibitors
- Drugs that interact with antihyperglycemics (e.g. trimethoprim/sulfamethoxazole with sulfonylureas)
- Drugs reported to cause hypoglycemia (e.g. alcohol, MAOIs, salicylates, quinolones, quinine, beta-blockers, ACEs, pentamidine)

Engaging patients and caregivers

- Some older adults prefer less intensive therapy, especially if burdensome or increases risk of hypoglycemia
- Patients and/or caregivers may be more likely to engage in discussion about changing targets or considering deprescribing if they understand the rationale:
 - Risks of hypoglycemia and other side effects
 - Risks of tight glucose control (no benefit and possible harm with A1C < 6%)
 - Time to benefit of tight glucose control
 - Reduced certainty about benefit of treatment with frailty, dementia or at end-of-life
- Goals of care: avoid hyperglycemic symptoms (thirst, dehydration, frequency, falls, fatigue, renal insufficiency) and prevent complications (5-10 years of treatment needed)
- Many countries agree on less aggressive treatment of diabetes in older persons
- Reviewing options for deprescribing, as well as the planned process for monitoring and thresholds for returning to previous doses, will help engage patients and caregivers

Hypoglycemia information for patients and caregivers

- Older frail adults are at higher risk of hypoglycemia
- There is a greater risk of hypoglycemia with tight control
- Symptoms of hypoglycemia include: sweating, tachycardia, tremor BUT older patients may not typically have these
- Cognitive or physical impairments may limit older patient's ability to respond to hypoglycemia symptoms
- Some drugs can mask the symptoms of hypoglycemia (e.g. beta blockers)
- Harms of hypoglycemia may be severe and include: impaired cognitive and physical function, falls and fractures, seizures, emergency room visits and hospitalizations

Tapering advice

- Set blood glucose & A1C targets, plus thresholds for returning to previous doses, restarting a drug or maintaining a dose
- Develop tapering plan with patient/caregiver (no evidence for one best tapering approach; can stop oral antihyperglycemics, switch drugs, or lower doses gradually e.g. changes every 1-4 weeks, to the minimum dose available prior to discontinuation, or simply deplete patient's supply)
- Doses may be increased or medication restarted any time if blood glucose persists above individual target (13-15 mmol/L) or symptomatic hyperglycemia returns

© Use freely, with credit to the authors. Not for commercial use. Do not modify or translate without permission.

The work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Contact: info@deprescribing.org or visit deprescribing.org for more information.


David S. Black, MD, Thompson W. McCarthy, MD, Margaret C. Lubner, MD, Sharon E. McKinnon, PhD, Richard W. Linder, MD

2016. Evidence-based clinical practice guideline for deprescribing antihyperglycemics. Unpublished manuscript.

35



deprescribing.org



Some cases to consider

Mr. B.

- 82 years of age
- Dizziness, impaired cognition, falls
- Community dwelling
- A1C of 7.2%; blood glucose ranges 4.0 to 9.0
- CrCl = 40ml/min
- On metformin 1g bid, sitagliptan 100mg daily, glyburide 10mg bid

Ms. F.

- 97 years of age
- 20 lb loss of weight
- Recently stopped HCTZ and metoprolol due to dizziness; still weak, confused, falling; frequent bronchitis treated with Septra
- Community dwelling
- A1C = 7.9%; clinic blood glucose 10-14
- CrCl = 30ml/min
- On metformin 1g bid, sitagliptan 100mg daily, glyburide 10mg bid and NPH 10 u qhs
- Enjoys evening glass of whiskey



deprescribing.org

For each case

- Is there an opportunity?
- Why do it?
 - Decide patient goals and targets (A1C & blood glucose)
- How? Determine what deprescribing steps need to be taken:
 - a) Reduce dose(s) or stop agent(s) most likely to contribute to hypoglycemia (e.g., sulfonylurea, insulin) or other adverse events
 - b) Switch to an agent with a lower risk of hypoglycemia
 - E.g. glyburide to gliclazide or non-sulfonylurea
 - c) Reduce doses of renally eliminated antihyperglycemics
 - E.g. metformin, sitagliptin
- What and how to monitor?



What else should be considered to minimize risk of hypoglycemia, reduce burden?

- Could a drug interaction be increasing hypoglycemic effect?
 - If so, consider reducing dose or stopping the offending interacting drug, or reduce AHG dose
- Has a medication that causes hyperglycemia recently been stopped?
 - Is so, AHG doses may need reduction
- Anything else?



For the elderly person with diabetes

- Older people with diabetes may be at risk of hypoglycemia, resulting in falls, fractures, cognitive impairment, seizures, and hospitalisation; risk is increased in the frail elderly
- Set individualized targets with avoidance of hypoglycemia in mind
- Engage patients in discussion about harms of continued AHG use, goals of deprescribing
- Collaborate with patient to develop goals and plan
- Monitoring and follow-up is extremely important



More resources



New online module

<http://www.bruyere.org/en/polypharmacy-deprescribing>

The screenshot shows the Bruyère website with a navigation bar and a sidebar menu. The main content area is titled 'Polypharmacy and Deprescribing' and includes a description of the module, its purpose, and a list of topics covered. The sidebar menu includes links to 'Education', 'Continuing Education', 'Quality of Care and Patient Safety Modules', 'How to Use MEDSTOPPER', 'Continuing Education', 'Creating Effective Evaluation Tools', 'Advance Care Planning', 'Cognitive Impairment and Driving', 'End of Life Care', 'Family Conferences', 'Polypharmacy and Deprescribing', and 'Resources'.



MEDSTOPPER

The screenshot shows the MEDSTOPPER website with a navigation bar and a search bar. The main content area is titled 'MEDSTOPPER BETA' and includes a description of the tool, its purpose, and a search for 'Medication Review'. The search results show a table with columns for 'Medication Review', 'Medication Review', 'Medication Review', and 'Medication Review'.


<http://medstopper.com/>

MedStopper Plan							
Change medication list: <input type="text" value="Sleeping Pills"/> <input type="button" value="Add New Medication"/> <input type="button" value="Cancel"/>							
Medication Category/Condition	Medication Category/Condition	Medication Category/Condition	Medication Category/Condition	Medication Category/Condition	Medication Category/Condition	Medication Category/Condition	Medication Category/Condition
Medication Category/Condition	Medication Category/Condition	Medication Category/Condition	Medication Category/Condition	Medication Category/Condition	Medication Category/Condition	Medication Category/Condition	Medication Category/Condition
Medication Category/Condition	Medication Category/Condition	Medication Category/Condition	Medication Category/Condition	Medication Category/Condition	Medication Category/Condition	Medication Category/Condition	Medication Category/Condition
Medication Category/Condition	Medication Category/Condition	Medication Category/Condition	Medication Category/Condition	Medication Category/Condition	Medication Category/Condition	Medication Category/Condition	Medication Category/Condition
Medication Category/Condition	Medication Category/Condition	Medication Category/Condition	Medication Category/Condition	Medication Category/Condition	Medication Category/Condition	Medication Category/Condition	Medication Category/Condition
Medication Category/Condition	Medication Category/Condition	Medication Category/Condition	Medication Category/Condition	Medication Category/Condition	Medication Category/Condition	Medication Category/Condition	Medication Category/Condition



<http://deprescribing.org/>

- Deprescribing guidelines and algorithms
- Patient information pamphlets
- EMPOWER brochures
- National stakeholders meetings
- Ongoing research projects
- Resources and links



5 Questions to Ask About Your Medications

The Institute for Safe Medication Practices Canada suggests five questions to ask your health provider about your medications, especially if you are on a number of drugs.

RxISK

This drug safety website provides resources and access to data on prescription drugs you can't get anywhere else. It includes questions to ask before you take a medication, a side effects checker, a drug interaction checker, and a self-quiz to find out if you may be on too many drugs. You can also look up drugs and safety information and report a side effect.

Therapeutics Letter (Reducing Polypharmacy: A Logical Approach)

This letter discusses the issues around elders who are on a multitude of drugs and suggests that medication regimes should be challenged routinely. Logical approaches to working with this problem are suggested.

In this section

- Deprescribing Algorithms
- Deprescribing Information Pamphlets
- Deprescribing Patient Decision Aids
- Helpful Links
- Patient and Clinician Stories
- Publications



More useful links to explore...

- <http://pathclinic.ca/resources/>
- <http://www.polypharmacy.scot.nhs.uk/>
- <http://www.bpac.org.nz/BPJ/2010/April/stopguide.aspx>
- <https://rxisk.org/>
- <http://sydney.edu.au/medicine/cdpc/documents/about/outcome-statement-national-stakeholders-meeting.pdf>
- <http://www.primaryhealthtas.com.au/resources/deprescribing>

23 April 2017

PROJET DE RECHERCHE
Bruyère



deprescribing.org

CaDeN
Canadian Deprescribing
Network



ReCaD
Réseau canadien
pour la déprescription

<http://deprescribing.org/caden/>

Less is More

The Canadian Deprescribing Network


PROJET DE RECHERCHE
Bruyère




deprescribing.org

Canadian Deprescribing Network (CaDeN)¹¹

- A network of patient advocates, health care professionals, researchers and health care leaders
- Optimize medication use and reduce harm through deprescribing
- Mission: to build capacity and catalyze action to promote deprescribing across Canada
- Two overarching goals:
 1. Reduce harm by curbing the prescription of inappropriate medications by 50% by 2020
 2. Promote health by ensuring access to safer pharmacological or non-pharmacological therapies



CaDeN's structure and timeline



Answers to self-assessment questions

- Deprescribing should be tested by recommending to patients that they periodically choose to stop taking medications (T/F)
FALSE
- Evidence-based deprescribing guidelines consider harm of continuing a drug in addition to evidence for the harm/benefit of stopping a drug (T/F)
TRUE
- There are not enough tools available to help make decisions about deprescribing (T/F)
FALSE

Take home messages

- Deprescribing is part of good prescribing – backing off when doses are too high or stopping medications no longer needed or where they are causing harm
- Evidence-based deprescribing guidelines help clinicians make decisions about when and how to reduce or stop medications safely
- Pharmacists have an important role in engaging patients in deprescribing discussions and helping prescribers make decisions about and monitoring impact of deprescribing

23 April 2017

INSTITUT DE RECHERCHE
Bruyère



deprescribing.org

It takes a village...



INSTITUT DE RECHERCHE
Bruyère



deprescribing.org

Contacts

- <http://deprescribing.org/> (Evidence-based guideline algorithms, EMPOWER brochures, other resources e.g. Medstopper, CaDeN, research summaries etc.)
- For deprescribing guidelines research:
 - <http://www.open-pharmacy-research.ca/research-projects/emerging-services/deprescribing-guidelines/>
 - deprescribing@bruyere.org
 - Follow us on twitter: @Deprescribing
- For CaDeN: annie.webb@criugm.qc.ca and @DeprescribeNet



Bibliography

1. Kwan D, Farrell B. Polypharmacy: optimizing medication use in elderly patients. CGS Journal of CME 2014;4(1):21-27
<http://canadiangeriatrics.ca/2014/05/volume-4-issue-polypharmacy/>
2. Page AT, Potter K, Clifford R, Etherton-Beer C. Deprescribing in older people. Maturitas 2016;91:115-124.
3. Seniors and Drugs: an in-depth look. CIHI 2014
https://www.cihi.ca/en/seniors_public_sum_en.pdf
4. Morgan S, Hunt J, Rioux J, Proulx J, Weymann D, Tannenbaum C. Frequency and cost of potentially inappropriate prescribing for older adults: a cross-sectional study. CMAJ OPEN 2016;4(2):E246-E351. doi.9778/cmajo.20150131
5. Reeve E, Farrell B, Thompson W. Deprescribing: a narrative review of the evidence and practical recommendations for recognizing opportunities and taking action. European Journal of Medicine 2017;38:3-11.



Bibliography

6. Farrell B, Tsang C, Raman-Wilms L, Irving H, Conklin J, Pottie K. What are priorities for deprescribing for elderly patients? Capturing the voice of practitioners: a modified Delphi process. PLoS One 2015;10(4):e0122246.
7. Conklin J, Farrell B, Ward N, McCarthy L, Irving H, Raman-Wilms L. Developmental evaluation as a strategy to enhance the uptake and use of deprescribing guidelines: protocol for a multiple case study. Implement Sci 2015;10(1):91. doi: 10.1186/s13012-015-0279-0.
8. Farrell B, Pottie K, Rojas-Fernandez C, Bjerre LM, Thompson W, Welch V. Methodology for developing deprescribing guidelines: using evidence and GRADE to guide recommendations for deprescribing. PLOS ONE 2016; August 12, 2016; available online: DOI: <http://dx.doi.org/10.1371/journal.pone.0161248>

23 April 2017


 Bruyère
RESEARCH CENTRE

 deprescribing.org

Bibliography

9. Farrell B, Richardson L, Raman-Wilms L, de Launay D, Alsabbagh MW, Conklin J. Self-efficacy for deprescribing: a survey for health care professionals using evidence-based deprescribing guidelines. Research in Social and Administrative Pharmacy 2017; (published online ahead of print). DOI: <http://dx.doi.org/10.1016/j.sapharm.2017.01.003>
10. Thompson W, Hogel M, Li Y, Thavorn K, O'Donnell D, McCarthy L, Dolovich L, Black C, Farrell B. Effect of a proton-pump inhibitor deprescribing guideline on drug usage and costs in long-term care. Journal of the American Medical Directors Association June 2016; available online: DOI: <http://dx.doi.org/10.1016/j.jamda.2016.04.020>
11. Tannenbaum C, Farrell B, Shaw J, Morgan S, Trimble J, Currie J, Turner J, Rochon P, Silvius J. An ecological approach to reducing potentially inappropriate medication use: Canadian Deprescribing Network. Canadian Journal on Aging 2017;36(1): 97-107.

23 April 2017


 Bruyère
RESEARCH CENTRE

 deprescribing.org



deprescribing.org

—
www.deprescribing.org
deprescribing@bruyere.org

[@deprescribing](https://twitter.com/deprescribing)
facebook.com/deprescribing.org
—

INSTITUT DE RECHERCHE
Bruyère 
RESEARCH INSTITUTE